ProQR Therapeutics NV
PRQR
$3.54
Closing
▲2.02%
1D
▲78.79%
YTD
PRQR
BBG006N8B849
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$374.90M
Analysts' Rating
BUY
Price Target (Mean)
4.28
Total Analysts
6
P/E
Operating Margin
-55.72%
Beta
0.22
Revenue Growth
419.79%
52 week high
$4.61
52 week low
$1.61
Div. Yield
%
EPS Growth
-66.24
Company Profile
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
